Regor Pharmaceuticals Inc.
Clinical trials sponsored by Regor Pharmaceuticals Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new oral drug tame advanced breast cancer? Results expected Dec 2026 (estimated)
- New hope for Hard-to-Treat breast cancer: first human trial begins Results expected Dec 2026 (estimated)
-
New hope for Hard-to-Treat breast cancer: first human trial begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called RGT-419B, given alone or with hormone therapy, in 64 adults with a specific type of advanced breast cancer (HR+/HER2-) that has worsened after prior treatment. The main goal is to check safety and find the right dose, while also…
Phase 1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…
Phase 1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC